Teriparatide on Maxillary Sinus Floor Osseointegration
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The aim of this triple blind randomized controlled trial will be to analyze the effect of a
dose of teriparatide combined with a xenograft on bone augmentation of the maxillary sinus,
to observe the microarchitecture of the newly formed bone and the primary and late stability
of implants placed on these grafts. The sample is composed of 42 participants who have a
clinical indication for maxillary sinus floor augmentation with bone grafting due to residual
bone height less than or equal to 5mm for the installation of dental implants. Each side will
be grafted with Bio-Oss® or Bio-Oss® combined with 1 dose (20 µg) of teriparatide (Forteo®).
Three months after grafting, at the time of placement of dental implants, bone biopsies will
be obtained using a short 2mm trephine bur. These bone cores will be submitted to
histological and histomorphometric analysis. The stability of the implants will be measured,
at the time of their installation, through the insertion torque, and through the use of
resonance frequency equipment (Ostell®) in three moments: immediately and at 3 and 6 months
after the installation of the dental implants.